A high quality and consistent product, supported by consistent service and reliable supply, balanced against the very best price – and all with maximum sustainability benefit.
We know exactly what our pharma customers want from a CMO partner: Peace of mind. At DSM we provide it through the development and manufacturing of APIs and intermediates across the entire lifecycle. We cater to both large pharmas looking for specific expertise and additional capacity at maximum efficiency; and to smaller, emerging customers where our economies of scale, track record and regulatory support can accelerate and simplify production.
Pre-clinical
We offer you a range of early-stage R&D services as well as the development and production of materials for tox studies and clinical trials. Our ResCom® solution focuses on fast supply of clinical trials materials (cGMP as well as non-GMP) and includes the development and implementation of chemical processes based on drug discovery. We complement this with a range of analytical and investigational services all aimed at getting APIs through the pipeline as quickly and safely as possible.
CT1
Our route scouting services use green chemistry technologies to optimize production through biocatalysis, homogeneous catalysis, and micro reactors: Good for people, planet and profit. Our InnoSyn™ solution, for example, is based on an interdisciplinary approach across pharmaceutical chemistry and biotechnology, which not only finds the best synthesis routes but also the routes for commercial scale up in API production.
We provide high quality molecule development (with no byproduct) and starter materials sourced from a network of hand-picked suppliers – providing not only reliability but also transparency, traceability - and of course (where commercially viable) sustainability.
CT2
As we move from the lab to limited production, it’s all about providing a smooth, safe transition and the optimum conditions for fast, reliable manufacturing - tailored to the very specific needs of each customer.
This is where our innovative technologies like the micro reactor and biocatalysis really benefit process improvement – enabling customers to produce higher volumes faster – yet in a more sustainable way using bio-based starter materials like enzymes. In fact we have an entire green chemistry toolbox dedicated to optimizing scale-up at speed.
CT3
At this critical stage of the lifecycle there’s a lot at stake - which is why tech transfer needs to be as smooth and predictable as possible. The track record of our production facilities are unsurpassed, offering the highest production quality – again aided by a range of process improvements.
Our experience enables us to scale up faster with fast reaction optimization, and all supporting process development ready for full-scale cGMP implementation.
Commercial
We provide flexible commercial manufacturing under full cGMP conditions while our dedicated team continues to search for new ways of optimizing processes and the chosen route.
Aside from manufacturing the APIs we also package them thanks to our dedicated Finished Dosage business based in the United States – able to provide a wide range of sterile and solid dosage forms as well as pharmaceutical development services including packaging. And perhaps most importantly of all, with DSM you are assured of security of supply and on time delivery – a critical factor for all our customers.
Off-patent
We’ve established a dedicated group for serving the market with our multicustomer products. With a range of applications in pharmaceuticals, injectable antibiotics, food and cosmetics, we provide the expertise and services necessary to meet market demand for our customers. Over the years we’ve developed a comprehensive library of generic APIs and intermediates and we also offer products from our partner, Indoco.
We can help customers optimize existing routes for their generic products; and we’re also now exploring the possibility of developing our own generic product portfolio based on second generation routes which we believe could significantly reduce costs.